Landmark Malaria Vaccine Launched In Malawi – Kenya, Ghana Next 23/04/2019 David Branigan The World Health Organization today announced that a new vaccine for malaria, which has been in development for 30 years and recently passed clinical trials, is being introduced as part of the routine childhood immunization programmes of Malawi, soon to be followed by Kenya and Ghana.Continue reading -> Image Credits: WHO/M. Nieuwenhof. PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and effective radical cure to prevent relapse. VivAccess’s work is funded by the Bill & Melinda Gates Foundation.Continue reading -> Image Credits: Damien Schumann/MMV. DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi).Continue reading -> Image Credits: MSF, DNDi, MSD. EU Health Ministers Meet To Discuss Access To Medicines And Treatment 18/04/2019 Editorial team European Union health ministers’ meeting last week in Romania addressed ways to ensure access to medicines and treatment, especially for youth or those with rare diseases. For innovative and expensive medicines, they discussed possibilities “for the time period between the granting of the marketing authorization, the actual placement on the market and the decision to reimburse the product in that Member State.”Continue reading -> New WHO Digital Health Guidelines Assess “Appropriateness” Of Technology Options 17/04/2019 David Branigan The World Health Organization’s new guidelines on digital health highlight the value of digital health technologies in helping to close health system gaps, while emphasising that they do not replace investments in health system infrastructure. The guidelines assess the appropriateness of a range of digital health technologies and provide recommendations on making informed investments in these technologies and how best to integrate them into health systems. The new WHO guidelines, Recommendations on Digital Interventions for Health System Strengthening, released today, present recommendations that “examine the extent to which digital health interventions, primarily available via mobile devices, are able to address health system challenges along the pathway to UHC [universal health coverage].” “Harnessing the power of digital technologies is essential for achieving universal health coverage,” WHO Director-General Dr Tedros Adhanom Ghebreyesus (Dr Tedros), said in a press release. “Ultimately, digital technologies are not ends in themselves; they are vital tools to promote health, keep the world safe, and serve the vulnerable.” The recommendations cover a range of technologies in the areas of birth and death notification by mobile device, stock notification and commodity management by mobile device, telemedicine between clients and providers, digital tracking of patients’ health status and services by mobile device, and health worker training and decision support by mobile device. “By reviewing the evidence of different digital interventions against comparative options, as well as assessing the risks,” the guidelines aim “to equip health policy-makers and other stakeholders with recommendations and implementation considerations for making informed investments into digital health interventions.” “Digital interventions depend heavily on the context and ensuring appropriate design,” Dr Garrett Mehl, WHO scientist in digital innovations and research, said in the release. “This includes structural issues in the settings where they are being used, available infrastructure, the health needs they are trying to address, and the ease of use of the technology itself.” The guidelines emphasise that “digital health interventions are not a substitute for functioning health systems, and that there are significant limitations to what digital health is able to address. Digital health interventions should complement and enhance health system functions through mechanisms such as accelerated exchange of information, but will not replace the fundamental components needed by health systems such as the health workforce, financing, leadership and governance, and access to essential medicines.” The guidelines also clearly prioritise the needs of vulnerable communities, stating that implementation of the recommendations “should not exclude or jeopardize the provision of quality non-digital services in places where there is no access to the digital technologies or [where] they are not acceptable or affordable for target communities.” “Digital health is not a silver bullet,” Bernardo Mariano, WHO’s chief information officer, said in the release. “WHO is working to make sure it’s used as effectively as possible. This means ensuring that it adds value to the health workers and individuals using these technologies, takes into account the infrastructural limitations, and that there is proper coordination.” Due to the rising interest in digital health technologies in recent years, many have been “rolled out in the absence of a careful examination of the evidence base on benefits and harms,” which, according to the guidelines, has “driven a proliferation of short-lived implementations and an overwhelming diversity of digital tools, with a limited understanding of their impact on health systems and people’s well-being.” “While recognizing the innovative role that digital technologies can play in strengthening the health system,” the guidelines conclude that “there is an equally important need to evaluate their contributing effects and ensure that such investments do not inappropriately divert resources from alternative, non-digital approaches.” The term “digital health” was introduced to encompass the previously applied terms eHealth (using information and communications technologies) and mHealth (using mobile technologies), while also incorporating emerging new technologies such as the advanced computing of “big data,” genomics and artificial intelligence. The guidelines were developed based upon the World Health Assembly Resolution on Digital Health, which was unanimously approved by WHO member states in 2018. According to the guidelines, this resolution “demonstrated a collective recognition of the value of digital technologies to contribute to advancing universal health coverage (UHC) and other health aims of the Sustainable Development Goals (SDGs).” In March 2019, WHO also announced a plan to create a new Department of Digital Health, “to enhance WHO’s role in assessing digital technologies and support Member States in prioritizing, integrating and regulating them,” according to the release. Image Credits: WHO. Huge European Parliament Majority Votes To Adopt The SPC Manufacturing Waiver 17/04/2019 Editorial team [Medicines for Europe Press Release] BRUSSELS, BELGIUM – 17 APRIL 2019 The European Parliament adopted the SPC manufacturing waiver with a huge majority. The waiver will improve access to medicine and create manufacturing job opportunities for Europe as of July 2022. Medicines for Europe will work with its members to facilitate the practical use of the waiver and will monitor and act against any potential misuse of the notification system for frivolous litigation. The European Parliament today voted overwhelmingly with 572 Members of Parliament in favour to adopt the Supplementary Protection Certificate (SPC) manufacturing waiver. The SPC manufacturing waiver is now expected to be formally adopted by the European Council in the coming weeks. Medicines for Europe commends the EU institutions for successfully concluding this important step in the adoption of the waiver. We congratulate the European Commission for proposing the waiver and the rapporteurs and shadow rapporteurs of the Legal, Trade and Health committees of the European Parliament as well as the European Council for substantially improving the manufacturing waiver to deliver access to medicines for European patients. The SPC manufacturing waiver will enable the European pharmaceutical industry to compete on a level playing field globally for manufacturing opportunities in generic and biosimilar medicines which is growing year on year. The waiver will come into force in July 2019 and companies will be able to start manufacturing under the waiver from July 2022. The Commission has evaluated the tremendous investments in new, high-skill jobs that this manufacturing for export and for day 1 launch can deliver for Europe[1]. The waiver’s notification measures should therefore not be misused to block generic and biosimilar medicines competition. Adrian van den Hoven, Director General of Medicines for Europe commented “Today’s vote on the SPC manufacturing waiver reflects the EU’s commitment to access to medicines, manufacturing jobs in Europe and putting EU industry on a level playing field globally. Europe has everything to gain from fully implementing the waiver to enable more competition on the pharmaceutical market and to improve its own security of medicines supply.” [1] https://ec.europa.eu/docsroom/documents/29463 DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug developmentContinue reading -> Image Credits: Atomwise. “Tax The Things That Are Killing Us” To Help Curb NCDs, New Report Recommends 16/04/2019 David Branigan Raising taxes on tobacco, alcohol and sugary beverage products by more than 50 percent could prevent more than 50 million premature deaths due to noncommunicable diseases (NCDs) over the next 50 years, while yielding over US$ 20 trillion in revenue. That is the conclusion of a report by a global task force headed by philanthropist Michael Bloomberg and economist Lawrence Summers.Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger.Continue reading -> Image Credits: Anna Wang/MMV. “Dialogue” Highlighted As Way Forward At Closure Of WHO Fair Pricing Forum 15/04/2019 Elaine Ruth Fletcher WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines. This critical next step was announced Saturday in a WHO press release following the close of the 2nd Fair Pricing Forum in Johannesburg, co-hosted by WHO and the Government of South Africa.Continue reading -> Image Credits: WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria 23/04/2019 Editorial team [Medicines for Malaria Venture Press Release] PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria. The initiative is part of the larger global effort to support malaria-endemic countries in the adoption and use of new and existing tools, to facilitate well-tolerated and effective radical cure to prevent relapse. VivAccess’s work is funded by the Bill & Melinda Gates Foundation.Continue reading -> Image Credits: Damien Schumann/MMV. DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi).Continue reading -> Image Credits: MSF, DNDi, MSD. EU Health Ministers Meet To Discuss Access To Medicines And Treatment 18/04/2019 Editorial team European Union health ministers’ meeting last week in Romania addressed ways to ensure access to medicines and treatment, especially for youth or those with rare diseases. For innovative and expensive medicines, they discussed possibilities “for the time period between the granting of the marketing authorization, the actual placement on the market and the decision to reimburse the product in that Member State.”Continue reading -> New WHO Digital Health Guidelines Assess “Appropriateness” Of Technology Options 17/04/2019 David Branigan The World Health Organization’s new guidelines on digital health highlight the value of digital health technologies in helping to close health system gaps, while emphasising that they do not replace investments in health system infrastructure. The guidelines assess the appropriateness of a range of digital health technologies and provide recommendations on making informed investments in these technologies and how best to integrate them into health systems. The new WHO guidelines, Recommendations on Digital Interventions for Health System Strengthening, released today, present recommendations that “examine the extent to which digital health interventions, primarily available via mobile devices, are able to address health system challenges along the pathway to UHC [universal health coverage].” “Harnessing the power of digital technologies is essential for achieving universal health coverage,” WHO Director-General Dr Tedros Adhanom Ghebreyesus (Dr Tedros), said in a press release. “Ultimately, digital technologies are not ends in themselves; they are vital tools to promote health, keep the world safe, and serve the vulnerable.” The recommendations cover a range of technologies in the areas of birth and death notification by mobile device, stock notification and commodity management by mobile device, telemedicine between clients and providers, digital tracking of patients’ health status and services by mobile device, and health worker training and decision support by mobile device. “By reviewing the evidence of different digital interventions against comparative options, as well as assessing the risks,” the guidelines aim “to equip health policy-makers and other stakeholders with recommendations and implementation considerations for making informed investments into digital health interventions.” “Digital interventions depend heavily on the context and ensuring appropriate design,” Dr Garrett Mehl, WHO scientist in digital innovations and research, said in the release. “This includes structural issues in the settings where they are being used, available infrastructure, the health needs they are trying to address, and the ease of use of the technology itself.” The guidelines emphasise that “digital health interventions are not a substitute for functioning health systems, and that there are significant limitations to what digital health is able to address. Digital health interventions should complement and enhance health system functions through mechanisms such as accelerated exchange of information, but will not replace the fundamental components needed by health systems such as the health workforce, financing, leadership and governance, and access to essential medicines.” The guidelines also clearly prioritise the needs of vulnerable communities, stating that implementation of the recommendations “should not exclude or jeopardize the provision of quality non-digital services in places where there is no access to the digital technologies or [where] they are not acceptable or affordable for target communities.” “Digital health is not a silver bullet,” Bernardo Mariano, WHO’s chief information officer, said in the release. “WHO is working to make sure it’s used as effectively as possible. This means ensuring that it adds value to the health workers and individuals using these technologies, takes into account the infrastructural limitations, and that there is proper coordination.” Due to the rising interest in digital health technologies in recent years, many have been “rolled out in the absence of a careful examination of the evidence base on benefits and harms,” which, according to the guidelines, has “driven a proliferation of short-lived implementations and an overwhelming diversity of digital tools, with a limited understanding of their impact on health systems and people’s well-being.” “While recognizing the innovative role that digital technologies can play in strengthening the health system,” the guidelines conclude that “there is an equally important need to evaluate their contributing effects and ensure that such investments do not inappropriately divert resources from alternative, non-digital approaches.” The term “digital health” was introduced to encompass the previously applied terms eHealth (using information and communications technologies) and mHealth (using mobile technologies), while also incorporating emerging new technologies such as the advanced computing of “big data,” genomics and artificial intelligence. The guidelines were developed based upon the World Health Assembly Resolution on Digital Health, which was unanimously approved by WHO member states in 2018. According to the guidelines, this resolution “demonstrated a collective recognition of the value of digital technologies to contribute to advancing universal health coverage (UHC) and other health aims of the Sustainable Development Goals (SDGs).” In March 2019, WHO also announced a plan to create a new Department of Digital Health, “to enhance WHO’s role in assessing digital technologies and support Member States in prioritizing, integrating and regulating them,” according to the release. Image Credits: WHO. Huge European Parliament Majority Votes To Adopt The SPC Manufacturing Waiver 17/04/2019 Editorial team [Medicines for Europe Press Release] BRUSSELS, BELGIUM – 17 APRIL 2019 The European Parliament adopted the SPC manufacturing waiver with a huge majority. The waiver will improve access to medicine and create manufacturing job opportunities for Europe as of July 2022. Medicines for Europe will work with its members to facilitate the practical use of the waiver and will monitor and act against any potential misuse of the notification system for frivolous litigation. The European Parliament today voted overwhelmingly with 572 Members of Parliament in favour to adopt the Supplementary Protection Certificate (SPC) manufacturing waiver. The SPC manufacturing waiver is now expected to be formally adopted by the European Council in the coming weeks. Medicines for Europe commends the EU institutions for successfully concluding this important step in the adoption of the waiver. We congratulate the European Commission for proposing the waiver and the rapporteurs and shadow rapporteurs of the Legal, Trade and Health committees of the European Parliament as well as the European Council for substantially improving the manufacturing waiver to deliver access to medicines for European patients. The SPC manufacturing waiver will enable the European pharmaceutical industry to compete on a level playing field globally for manufacturing opportunities in generic and biosimilar medicines which is growing year on year. The waiver will come into force in July 2019 and companies will be able to start manufacturing under the waiver from July 2022. The Commission has evaluated the tremendous investments in new, high-skill jobs that this manufacturing for export and for day 1 launch can deliver for Europe[1]. The waiver’s notification measures should therefore not be misused to block generic and biosimilar medicines competition. Adrian van den Hoven, Director General of Medicines for Europe commented “Today’s vote on the SPC manufacturing waiver reflects the EU’s commitment to access to medicines, manufacturing jobs in Europe and putting EU industry on a level playing field globally. Europe has everything to gain from fully implementing the waiver to enable more competition on the pharmaceutical market and to improve its own security of medicines supply.” [1] https://ec.europa.eu/docsroom/documents/29463 DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug developmentContinue reading -> Image Credits: Atomwise. “Tax The Things That Are Killing Us” To Help Curb NCDs, New Report Recommends 16/04/2019 David Branigan Raising taxes on tobacco, alcohol and sugary beverage products by more than 50 percent could prevent more than 50 million premature deaths due to noncommunicable diseases (NCDs) over the next 50 years, while yielding over US$ 20 trillion in revenue. That is the conclusion of a report by a global task force headed by philanthropist Michael Bloomberg and economist Lawrence Summers.Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger.Continue reading -> Image Credits: Anna Wang/MMV. “Dialogue” Highlighted As Way Forward At Closure Of WHO Fair Pricing Forum 15/04/2019 Elaine Ruth Fletcher WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines. This critical next step was announced Saturday in a WHO press release following the close of the 2nd Fair Pricing Forum in Johannesburg, co-hosted by WHO and the Government of South Africa.Continue reading -> Image Credits: WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises 18/04/2019 Elaine Ruth Fletcher Global health policymakers need to adopt a “bench-to-bedside” approach to research and development, to ensure that new drugs and vaccines are not only put into the development pipeline, but are also readily available for responding to global health crises such as Ebola, says Michelle Childs of the Drugs for Neglected Diseases Initiative (DNDi).Continue reading -> Image Credits: MSF, DNDi, MSD. EU Health Ministers Meet To Discuss Access To Medicines And Treatment 18/04/2019 Editorial team European Union health ministers’ meeting last week in Romania addressed ways to ensure access to medicines and treatment, especially for youth or those with rare diseases. For innovative and expensive medicines, they discussed possibilities “for the time period between the granting of the marketing authorization, the actual placement on the market and the decision to reimburse the product in that Member State.”Continue reading -> New WHO Digital Health Guidelines Assess “Appropriateness” Of Technology Options 17/04/2019 David Branigan The World Health Organization’s new guidelines on digital health highlight the value of digital health technologies in helping to close health system gaps, while emphasising that they do not replace investments in health system infrastructure. The guidelines assess the appropriateness of a range of digital health technologies and provide recommendations on making informed investments in these technologies and how best to integrate them into health systems. The new WHO guidelines, Recommendations on Digital Interventions for Health System Strengthening, released today, present recommendations that “examine the extent to which digital health interventions, primarily available via mobile devices, are able to address health system challenges along the pathway to UHC [universal health coverage].” “Harnessing the power of digital technologies is essential for achieving universal health coverage,” WHO Director-General Dr Tedros Adhanom Ghebreyesus (Dr Tedros), said in a press release. “Ultimately, digital technologies are not ends in themselves; they are vital tools to promote health, keep the world safe, and serve the vulnerable.” The recommendations cover a range of technologies in the areas of birth and death notification by mobile device, stock notification and commodity management by mobile device, telemedicine between clients and providers, digital tracking of patients’ health status and services by mobile device, and health worker training and decision support by mobile device. “By reviewing the evidence of different digital interventions against comparative options, as well as assessing the risks,” the guidelines aim “to equip health policy-makers and other stakeholders with recommendations and implementation considerations for making informed investments into digital health interventions.” “Digital interventions depend heavily on the context and ensuring appropriate design,” Dr Garrett Mehl, WHO scientist in digital innovations and research, said in the release. “This includes structural issues in the settings where they are being used, available infrastructure, the health needs they are trying to address, and the ease of use of the technology itself.” The guidelines emphasise that “digital health interventions are not a substitute for functioning health systems, and that there are significant limitations to what digital health is able to address. Digital health interventions should complement and enhance health system functions through mechanisms such as accelerated exchange of information, but will not replace the fundamental components needed by health systems such as the health workforce, financing, leadership and governance, and access to essential medicines.” The guidelines also clearly prioritise the needs of vulnerable communities, stating that implementation of the recommendations “should not exclude or jeopardize the provision of quality non-digital services in places where there is no access to the digital technologies or [where] they are not acceptable or affordable for target communities.” “Digital health is not a silver bullet,” Bernardo Mariano, WHO’s chief information officer, said in the release. “WHO is working to make sure it’s used as effectively as possible. This means ensuring that it adds value to the health workers and individuals using these technologies, takes into account the infrastructural limitations, and that there is proper coordination.” Due to the rising interest in digital health technologies in recent years, many have been “rolled out in the absence of a careful examination of the evidence base on benefits and harms,” which, according to the guidelines, has “driven a proliferation of short-lived implementations and an overwhelming diversity of digital tools, with a limited understanding of their impact on health systems and people’s well-being.” “While recognizing the innovative role that digital technologies can play in strengthening the health system,” the guidelines conclude that “there is an equally important need to evaluate their contributing effects and ensure that such investments do not inappropriately divert resources from alternative, non-digital approaches.” The term “digital health” was introduced to encompass the previously applied terms eHealth (using information and communications technologies) and mHealth (using mobile technologies), while also incorporating emerging new technologies such as the advanced computing of “big data,” genomics and artificial intelligence. The guidelines were developed based upon the World Health Assembly Resolution on Digital Health, which was unanimously approved by WHO member states in 2018. According to the guidelines, this resolution “demonstrated a collective recognition of the value of digital technologies to contribute to advancing universal health coverage (UHC) and other health aims of the Sustainable Development Goals (SDGs).” In March 2019, WHO also announced a plan to create a new Department of Digital Health, “to enhance WHO’s role in assessing digital technologies and support Member States in prioritizing, integrating and regulating them,” according to the release. Image Credits: WHO. Huge European Parliament Majority Votes To Adopt The SPC Manufacturing Waiver 17/04/2019 Editorial team [Medicines for Europe Press Release] BRUSSELS, BELGIUM – 17 APRIL 2019 The European Parliament adopted the SPC manufacturing waiver with a huge majority. The waiver will improve access to medicine and create manufacturing job opportunities for Europe as of July 2022. Medicines for Europe will work with its members to facilitate the practical use of the waiver and will monitor and act against any potential misuse of the notification system for frivolous litigation. The European Parliament today voted overwhelmingly with 572 Members of Parliament in favour to adopt the Supplementary Protection Certificate (SPC) manufacturing waiver. The SPC manufacturing waiver is now expected to be formally adopted by the European Council in the coming weeks. Medicines for Europe commends the EU institutions for successfully concluding this important step in the adoption of the waiver. We congratulate the European Commission for proposing the waiver and the rapporteurs and shadow rapporteurs of the Legal, Trade and Health committees of the European Parliament as well as the European Council for substantially improving the manufacturing waiver to deliver access to medicines for European patients. The SPC manufacturing waiver will enable the European pharmaceutical industry to compete on a level playing field globally for manufacturing opportunities in generic and biosimilar medicines which is growing year on year. The waiver will come into force in July 2019 and companies will be able to start manufacturing under the waiver from July 2022. The Commission has evaluated the tremendous investments in new, high-skill jobs that this manufacturing for export and for day 1 launch can deliver for Europe[1]. The waiver’s notification measures should therefore not be misused to block generic and biosimilar medicines competition. Adrian van den Hoven, Director General of Medicines for Europe commented “Today’s vote on the SPC manufacturing waiver reflects the EU’s commitment to access to medicines, manufacturing jobs in Europe and putting EU industry on a level playing field globally. Europe has everything to gain from fully implementing the waiver to enable more competition on the pharmaceutical market and to improve its own security of medicines supply.” [1] https://ec.europa.eu/docsroom/documents/29463 DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug developmentContinue reading -> Image Credits: Atomwise. “Tax The Things That Are Killing Us” To Help Curb NCDs, New Report Recommends 16/04/2019 David Branigan Raising taxes on tobacco, alcohol and sugary beverage products by more than 50 percent could prevent more than 50 million premature deaths due to noncommunicable diseases (NCDs) over the next 50 years, while yielding over US$ 20 trillion in revenue. That is the conclusion of a report by a global task force headed by philanthropist Michael Bloomberg and economist Lawrence Summers.Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger.Continue reading -> Image Credits: Anna Wang/MMV. “Dialogue” Highlighted As Way Forward At Closure Of WHO Fair Pricing Forum 15/04/2019 Elaine Ruth Fletcher WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines. This critical next step was announced Saturday in a WHO press release following the close of the 2nd Fair Pricing Forum in Johannesburg, co-hosted by WHO and the Government of South Africa.Continue reading -> Image Credits: WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
EU Health Ministers Meet To Discuss Access To Medicines And Treatment 18/04/2019 Editorial team European Union health ministers’ meeting last week in Romania addressed ways to ensure access to medicines and treatment, especially for youth or those with rare diseases. For innovative and expensive medicines, they discussed possibilities “for the time period between the granting of the marketing authorization, the actual placement on the market and the decision to reimburse the product in that Member State.”Continue reading -> New WHO Digital Health Guidelines Assess “Appropriateness” Of Technology Options 17/04/2019 David Branigan The World Health Organization’s new guidelines on digital health highlight the value of digital health technologies in helping to close health system gaps, while emphasising that they do not replace investments in health system infrastructure. The guidelines assess the appropriateness of a range of digital health technologies and provide recommendations on making informed investments in these technologies and how best to integrate them into health systems. The new WHO guidelines, Recommendations on Digital Interventions for Health System Strengthening, released today, present recommendations that “examine the extent to which digital health interventions, primarily available via mobile devices, are able to address health system challenges along the pathway to UHC [universal health coverage].” “Harnessing the power of digital technologies is essential for achieving universal health coverage,” WHO Director-General Dr Tedros Adhanom Ghebreyesus (Dr Tedros), said in a press release. “Ultimately, digital technologies are not ends in themselves; they are vital tools to promote health, keep the world safe, and serve the vulnerable.” The recommendations cover a range of technologies in the areas of birth and death notification by mobile device, stock notification and commodity management by mobile device, telemedicine between clients and providers, digital tracking of patients’ health status and services by mobile device, and health worker training and decision support by mobile device. “By reviewing the evidence of different digital interventions against comparative options, as well as assessing the risks,” the guidelines aim “to equip health policy-makers and other stakeholders with recommendations and implementation considerations for making informed investments into digital health interventions.” “Digital interventions depend heavily on the context and ensuring appropriate design,” Dr Garrett Mehl, WHO scientist in digital innovations and research, said in the release. “This includes structural issues in the settings where they are being used, available infrastructure, the health needs they are trying to address, and the ease of use of the technology itself.” The guidelines emphasise that “digital health interventions are not a substitute for functioning health systems, and that there are significant limitations to what digital health is able to address. Digital health interventions should complement and enhance health system functions through mechanisms such as accelerated exchange of information, but will not replace the fundamental components needed by health systems such as the health workforce, financing, leadership and governance, and access to essential medicines.” The guidelines also clearly prioritise the needs of vulnerable communities, stating that implementation of the recommendations “should not exclude or jeopardize the provision of quality non-digital services in places where there is no access to the digital technologies or [where] they are not acceptable or affordable for target communities.” “Digital health is not a silver bullet,” Bernardo Mariano, WHO’s chief information officer, said in the release. “WHO is working to make sure it’s used as effectively as possible. This means ensuring that it adds value to the health workers and individuals using these technologies, takes into account the infrastructural limitations, and that there is proper coordination.” Due to the rising interest in digital health technologies in recent years, many have been “rolled out in the absence of a careful examination of the evidence base on benefits and harms,” which, according to the guidelines, has “driven a proliferation of short-lived implementations and an overwhelming diversity of digital tools, with a limited understanding of their impact on health systems and people’s well-being.” “While recognizing the innovative role that digital technologies can play in strengthening the health system,” the guidelines conclude that “there is an equally important need to evaluate their contributing effects and ensure that such investments do not inappropriately divert resources from alternative, non-digital approaches.” The term “digital health” was introduced to encompass the previously applied terms eHealth (using information and communications technologies) and mHealth (using mobile technologies), while also incorporating emerging new technologies such as the advanced computing of “big data,” genomics and artificial intelligence. The guidelines were developed based upon the World Health Assembly Resolution on Digital Health, which was unanimously approved by WHO member states in 2018. According to the guidelines, this resolution “demonstrated a collective recognition of the value of digital technologies to contribute to advancing universal health coverage (UHC) and other health aims of the Sustainable Development Goals (SDGs).” In March 2019, WHO also announced a plan to create a new Department of Digital Health, “to enhance WHO’s role in assessing digital technologies and support Member States in prioritizing, integrating and regulating them,” according to the release. Image Credits: WHO. Huge European Parliament Majority Votes To Adopt The SPC Manufacturing Waiver 17/04/2019 Editorial team [Medicines for Europe Press Release] BRUSSELS, BELGIUM – 17 APRIL 2019 The European Parliament adopted the SPC manufacturing waiver with a huge majority. The waiver will improve access to medicine and create manufacturing job opportunities for Europe as of July 2022. Medicines for Europe will work with its members to facilitate the practical use of the waiver and will monitor and act against any potential misuse of the notification system for frivolous litigation. The European Parliament today voted overwhelmingly with 572 Members of Parliament in favour to adopt the Supplementary Protection Certificate (SPC) manufacturing waiver. The SPC manufacturing waiver is now expected to be formally adopted by the European Council in the coming weeks. Medicines for Europe commends the EU institutions for successfully concluding this important step in the adoption of the waiver. We congratulate the European Commission for proposing the waiver and the rapporteurs and shadow rapporteurs of the Legal, Trade and Health committees of the European Parliament as well as the European Council for substantially improving the manufacturing waiver to deliver access to medicines for European patients. The SPC manufacturing waiver will enable the European pharmaceutical industry to compete on a level playing field globally for manufacturing opportunities in generic and biosimilar medicines which is growing year on year. The waiver will come into force in July 2019 and companies will be able to start manufacturing under the waiver from July 2022. The Commission has evaluated the tremendous investments in new, high-skill jobs that this manufacturing for export and for day 1 launch can deliver for Europe[1]. The waiver’s notification measures should therefore not be misused to block generic and biosimilar medicines competition. Adrian van den Hoven, Director General of Medicines for Europe commented “Today’s vote on the SPC manufacturing waiver reflects the EU’s commitment to access to medicines, manufacturing jobs in Europe and putting EU industry on a level playing field globally. Europe has everything to gain from fully implementing the waiver to enable more competition on the pharmaceutical market and to improve its own security of medicines supply.” [1] https://ec.europa.eu/docsroom/documents/29463 DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug developmentContinue reading -> Image Credits: Atomwise. “Tax The Things That Are Killing Us” To Help Curb NCDs, New Report Recommends 16/04/2019 David Branigan Raising taxes on tobacco, alcohol and sugary beverage products by more than 50 percent could prevent more than 50 million premature deaths due to noncommunicable diseases (NCDs) over the next 50 years, while yielding over US$ 20 trillion in revenue. That is the conclusion of a report by a global task force headed by philanthropist Michael Bloomberg and economist Lawrence Summers.Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger.Continue reading -> Image Credits: Anna Wang/MMV. “Dialogue” Highlighted As Way Forward At Closure Of WHO Fair Pricing Forum 15/04/2019 Elaine Ruth Fletcher WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines. This critical next step was announced Saturday in a WHO press release following the close of the 2nd Fair Pricing Forum in Johannesburg, co-hosted by WHO and the Government of South Africa.Continue reading -> Image Credits: WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New WHO Digital Health Guidelines Assess “Appropriateness” Of Technology Options 17/04/2019 David Branigan The World Health Organization’s new guidelines on digital health highlight the value of digital health technologies in helping to close health system gaps, while emphasising that they do not replace investments in health system infrastructure. The guidelines assess the appropriateness of a range of digital health technologies and provide recommendations on making informed investments in these technologies and how best to integrate them into health systems. The new WHO guidelines, Recommendations on Digital Interventions for Health System Strengthening, released today, present recommendations that “examine the extent to which digital health interventions, primarily available via mobile devices, are able to address health system challenges along the pathway to UHC [universal health coverage].” “Harnessing the power of digital technologies is essential for achieving universal health coverage,” WHO Director-General Dr Tedros Adhanom Ghebreyesus (Dr Tedros), said in a press release. “Ultimately, digital technologies are not ends in themselves; they are vital tools to promote health, keep the world safe, and serve the vulnerable.” The recommendations cover a range of technologies in the areas of birth and death notification by mobile device, stock notification and commodity management by mobile device, telemedicine between clients and providers, digital tracking of patients’ health status and services by mobile device, and health worker training and decision support by mobile device. “By reviewing the evidence of different digital interventions against comparative options, as well as assessing the risks,” the guidelines aim “to equip health policy-makers and other stakeholders with recommendations and implementation considerations for making informed investments into digital health interventions.” “Digital interventions depend heavily on the context and ensuring appropriate design,” Dr Garrett Mehl, WHO scientist in digital innovations and research, said in the release. “This includes structural issues in the settings where they are being used, available infrastructure, the health needs they are trying to address, and the ease of use of the technology itself.” The guidelines emphasise that “digital health interventions are not a substitute for functioning health systems, and that there are significant limitations to what digital health is able to address. Digital health interventions should complement and enhance health system functions through mechanisms such as accelerated exchange of information, but will not replace the fundamental components needed by health systems such as the health workforce, financing, leadership and governance, and access to essential medicines.” The guidelines also clearly prioritise the needs of vulnerable communities, stating that implementation of the recommendations “should not exclude or jeopardize the provision of quality non-digital services in places where there is no access to the digital technologies or [where] they are not acceptable or affordable for target communities.” “Digital health is not a silver bullet,” Bernardo Mariano, WHO’s chief information officer, said in the release. “WHO is working to make sure it’s used as effectively as possible. This means ensuring that it adds value to the health workers and individuals using these technologies, takes into account the infrastructural limitations, and that there is proper coordination.” Due to the rising interest in digital health technologies in recent years, many have been “rolled out in the absence of a careful examination of the evidence base on benefits and harms,” which, according to the guidelines, has “driven a proliferation of short-lived implementations and an overwhelming diversity of digital tools, with a limited understanding of their impact on health systems and people’s well-being.” “While recognizing the innovative role that digital technologies can play in strengthening the health system,” the guidelines conclude that “there is an equally important need to evaluate their contributing effects and ensure that such investments do not inappropriately divert resources from alternative, non-digital approaches.” The term “digital health” was introduced to encompass the previously applied terms eHealth (using information and communications technologies) and mHealth (using mobile technologies), while also incorporating emerging new technologies such as the advanced computing of “big data,” genomics and artificial intelligence. The guidelines were developed based upon the World Health Assembly Resolution on Digital Health, which was unanimously approved by WHO member states in 2018. According to the guidelines, this resolution “demonstrated a collective recognition of the value of digital technologies to contribute to advancing universal health coverage (UHC) and other health aims of the Sustainable Development Goals (SDGs).” In March 2019, WHO also announced a plan to create a new Department of Digital Health, “to enhance WHO’s role in assessing digital technologies and support Member States in prioritizing, integrating and regulating them,” according to the release. Image Credits: WHO. Huge European Parliament Majority Votes To Adopt The SPC Manufacturing Waiver 17/04/2019 Editorial team [Medicines for Europe Press Release] BRUSSELS, BELGIUM – 17 APRIL 2019 The European Parliament adopted the SPC manufacturing waiver with a huge majority. The waiver will improve access to medicine and create manufacturing job opportunities for Europe as of July 2022. Medicines for Europe will work with its members to facilitate the practical use of the waiver and will monitor and act against any potential misuse of the notification system for frivolous litigation. The European Parliament today voted overwhelmingly with 572 Members of Parliament in favour to adopt the Supplementary Protection Certificate (SPC) manufacturing waiver. The SPC manufacturing waiver is now expected to be formally adopted by the European Council in the coming weeks. Medicines for Europe commends the EU institutions for successfully concluding this important step in the adoption of the waiver. We congratulate the European Commission for proposing the waiver and the rapporteurs and shadow rapporteurs of the Legal, Trade and Health committees of the European Parliament as well as the European Council for substantially improving the manufacturing waiver to deliver access to medicines for European patients. The SPC manufacturing waiver will enable the European pharmaceutical industry to compete on a level playing field globally for manufacturing opportunities in generic and biosimilar medicines which is growing year on year. The waiver will come into force in July 2019 and companies will be able to start manufacturing under the waiver from July 2022. The Commission has evaluated the tremendous investments in new, high-skill jobs that this manufacturing for export and for day 1 launch can deliver for Europe[1]. The waiver’s notification measures should therefore not be misused to block generic and biosimilar medicines competition. Adrian van den Hoven, Director General of Medicines for Europe commented “Today’s vote on the SPC manufacturing waiver reflects the EU’s commitment to access to medicines, manufacturing jobs in Europe and putting EU industry on a level playing field globally. Europe has everything to gain from fully implementing the waiver to enable more competition on the pharmaceutical market and to improve its own security of medicines supply.” [1] https://ec.europa.eu/docsroom/documents/29463 DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug developmentContinue reading -> Image Credits: Atomwise. “Tax The Things That Are Killing Us” To Help Curb NCDs, New Report Recommends 16/04/2019 David Branigan Raising taxes on tobacco, alcohol and sugary beverage products by more than 50 percent could prevent more than 50 million premature deaths due to noncommunicable diseases (NCDs) over the next 50 years, while yielding over US$ 20 trillion in revenue. That is the conclusion of a report by a global task force headed by philanthropist Michael Bloomberg and economist Lawrence Summers.Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger.Continue reading -> Image Credits: Anna Wang/MMV. “Dialogue” Highlighted As Way Forward At Closure Of WHO Fair Pricing Forum 15/04/2019 Elaine Ruth Fletcher WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines. This critical next step was announced Saturday in a WHO press release following the close of the 2nd Fair Pricing Forum in Johannesburg, co-hosted by WHO and the Government of South Africa.Continue reading -> Image Credits: WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Huge European Parliament Majority Votes To Adopt The SPC Manufacturing Waiver 17/04/2019 Editorial team [Medicines for Europe Press Release] BRUSSELS, BELGIUM – 17 APRIL 2019 The European Parliament adopted the SPC manufacturing waiver with a huge majority. The waiver will improve access to medicine and create manufacturing job opportunities for Europe as of July 2022. Medicines for Europe will work with its members to facilitate the practical use of the waiver and will monitor and act against any potential misuse of the notification system for frivolous litigation. The European Parliament today voted overwhelmingly with 572 Members of Parliament in favour to adopt the Supplementary Protection Certificate (SPC) manufacturing waiver. The SPC manufacturing waiver is now expected to be formally adopted by the European Council in the coming weeks. Medicines for Europe commends the EU institutions for successfully concluding this important step in the adoption of the waiver. We congratulate the European Commission for proposing the waiver and the rapporteurs and shadow rapporteurs of the Legal, Trade and Health committees of the European Parliament as well as the European Council for substantially improving the manufacturing waiver to deliver access to medicines for European patients. The SPC manufacturing waiver will enable the European pharmaceutical industry to compete on a level playing field globally for manufacturing opportunities in generic and biosimilar medicines which is growing year on year. The waiver will come into force in July 2019 and companies will be able to start manufacturing under the waiver from July 2022. The Commission has evaluated the tremendous investments in new, high-skill jobs that this manufacturing for export and for day 1 launch can deliver for Europe[1]. The waiver’s notification measures should therefore not be misused to block generic and biosimilar medicines competition. Adrian van den Hoven, Director General of Medicines for Europe commented “Today’s vote on the SPC manufacturing waiver reflects the EU’s commitment to access to medicines, manufacturing jobs in Europe and putting EU industry on a level playing field globally. Europe has everything to gain from fully implementing the waiver to enable more competition on the pharmaceutical market and to improve its own security of medicines supply.” [1] https://ec.europa.eu/docsroom/documents/29463 DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug developmentContinue reading -> Image Credits: Atomwise. “Tax The Things That Are Killing Us” To Help Curb NCDs, New Report Recommends 16/04/2019 David Branigan Raising taxes on tobacco, alcohol and sugary beverage products by more than 50 percent could prevent more than 50 million premature deaths due to noncommunicable diseases (NCDs) over the next 50 years, while yielding over US$ 20 trillion in revenue. That is the conclusion of a report by a global task force headed by philanthropist Michael Bloomberg and economist Lawrence Summers.Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger.Continue reading -> Image Credits: Anna Wang/MMV. “Dialogue” Highlighted As Way Forward At Closure Of WHO Fair Pricing Forum 15/04/2019 Elaine Ruth Fletcher WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines. This critical next step was announced Saturday in a WHO press release following the close of the 2nd Fair Pricing Forum in Johannesburg, co-hosted by WHO and the Government of South Africa.Continue reading -> Image Credits: WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases 17/04/2019 Editorial team [DNDi Press Release] Geneva, Switzerland and San Francisco, USA – 16 April 2019 Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug developmentContinue reading -> Image Credits: Atomwise. “Tax The Things That Are Killing Us” To Help Curb NCDs, New Report Recommends 16/04/2019 David Branigan Raising taxes on tobacco, alcohol and sugary beverage products by more than 50 percent could prevent more than 50 million premature deaths due to noncommunicable diseases (NCDs) over the next 50 years, while yielding over US$ 20 trillion in revenue. That is the conclusion of a report by a global task force headed by philanthropist Michael Bloomberg and economist Lawrence Summers.Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger.Continue reading -> Image Credits: Anna Wang/MMV. “Dialogue” Highlighted As Way Forward At Closure Of WHO Fair Pricing Forum 15/04/2019 Elaine Ruth Fletcher WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines. This critical next step was announced Saturday in a WHO press release following the close of the 2nd Fair Pricing Forum in Johannesburg, co-hosted by WHO and the Government of South Africa.Continue reading -> Image Credits: WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
“Tax The Things That Are Killing Us” To Help Curb NCDs, New Report Recommends 16/04/2019 David Branigan Raising taxes on tobacco, alcohol and sugary beverage products by more than 50 percent could prevent more than 50 million premature deaths due to noncommunicable diseases (NCDs) over the next 50 years, while yielding over US$ 20 trillion in revenue. That is the conclusion of a report by a global task force headed by philanthropist Michael Bloomberg and economist Lawrence Summers.Continue reading -> Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger.Continue reading -> Image Credits: Anna Wang/MMV. “Dialogue” Highlighted As Way Forward At Closure Of WHO Fair Pricing Forum 15/04/2019 Elaine Ruth Fletcher WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines. This critical next step was announced Saturday in a WHO press release following the close of the 2nd Fair Pricing Forum in Johannesburg, co-hosted by WHO and the Government of South Africa.Continue reading -> Image Credits: WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Europe-Africa partnership spearheads development of next-generation antimalarial drug 16/04/2019 Editorial team [Medicines for Malaria Venture Press Release] The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger.Continue reading -> Image Credits: Anna Wang/MMV. “Dialogue” Highlighted As Way Forward At Closure Of WHO Fair Pricing Forum 15/04/2019 Elaine Ruth Fletcher WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines. This critical next step was announced Saturday in a WHO press release following the close of the 2nd Fair Pricing Forum in Johannesburg, co-hosted by WHO and the Government of South Africa.Continue reading -> Image Credits: WHO. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
“Dialogue” Highlighted As Way Forward At Closure Of WHO Fair Pricing Forum 15/04/2019 Elaine Ruth Fletcher WHO said that it will launch a public online consultation involving governments, industry and civil society to try to come up with a broad consensus on what actually constitutes a “fair price” for essential medicines. This critical next step was announced Saturday in a WHO press release following the close of the 2nd Fair Pricing Forum in Johannesburg, co-hosted by WHO and the Government of South Africa.Continue reading -> Image Credits: WHO. Posts navigation Older postsNewer posts